Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada. tony.george@utoronto.ca
Tobacco addiction is the most significant preventable cause of morbidity and mortality in the Western world, with >430,000 deaths annually from tobacco-related diseases being reported in the United States. Although effective treatments are available for cessation of smoking (e.g., nicotine replacement therapies, sustained-release bupropion and varenicline), they do not work for all smokers. Therefore the development of more effective medications for treating tobacco dependence, based on novel mechanisms, is a high priority. This article reviews the links between smoking and monoamine oxidase (MAO) inhibition, which could lead to the development of novel pharmacotherapies to treat tobacco dependence.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on